Khan Sana, Giuliani Anna, Crepaldi Carlo, Ronco Claudio, Rosner Mitchell H
Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA.
Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy.
Perit Dial Int. 2017 Jul-Aug;37(4):384-388. doi: 10.3747/pdi.2016.00273.
End-stage renal disease secondary to autosomal dominant polycystic kidney (ADPKD) is a common issue worldwide. Peritoneal dialysis (PD) is a reasonable option for renal replacement therapy for these patients and should not be withheld due to concerns that the patient may not tolerate the fluid volumes in the peritoneal cavity. This review covers the existing data on the outcomes and complications associated with the use of PD in the polycystic kidney disease patient. In general, PD is well tolerated and outcomes in ADPKD patients are equivalent to or better than other patient groups.
常染色体显性多囊肾病（ADPKD）继发的终末期肾病在全球都是一个常见问题。腹膜透析（PD）是这些患者进行肾脏替代治疗的合理选择，不应因担心患者无法耐受腹膜腔内的液体量而不予采用。本综述涵盖了有关多囊肾病患者使用PD的结局和并发症的现有数据。总体而言，PD耐受性良好，ADPKD患者的结局与其他患者群体相当或更好。
